Recent Updates — RAPH

Ajay Kumar Dhadha resigned as Chairman of the Board and Director effective June 30, 2026. Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. The company appointed Uri Tadelis as Chief Financial Officer effective July 16, 2026. Neither resignation resulted from disagreements regarding company operations, policies, or financial reporting. Raphael Pharmaceutical Inc. operates in the pharmaceutical industry and develops medical treatments.